BMY

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Bristol-Myers Squibb Co.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
CEO
Giovanni Caforio
Employees
30250
Headquarters

430 E 29th St Fl 14
New York, New York 10016-8367
Phone: 12125464000
www.bms.com

News

Bristol Myers Stock (NYSE:BMY): Perfect Place to Wait Out Market Volatility
Aug 08, 2024 20:40pm

Healthcare giant Bristol-Myers Squibb ($BMY) looks like the perfect place to wait out the extreme volatility that has hit the market this summer. T…


Source:TipRanks
Evotec Announces Progress In Strategic Neuroscience Collaboration With Bristol Myers Squibb
Aug 08, 2024 06:42am

NEW YORK CITY (dpa-AFX) - Germany-headquartered drug manufacturer Evotec SE (EVT, EVO) on Thursday announced progress in the company''s strategic partnership with U.S.-based drug manufacturer Brist…


Source:Finanz Nachrichten
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
Aug 08, 2024 05:50am

Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / August 8, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: … Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb | EVO Stock News
Aug 08, 2024 05:50am

Evotec''s neuroscience partnership with Bristol Myers Squibb advances, securing $25M payment. Discover how this collaboration is driving innovative treatments for neurodegenerative diseases and shaping the future of medicine.


Source:Stock Titan
Bristol Myers cited by FDA for misleading claims on Krazati website
Aug 07, 2024 17:53pm

FDA issues untitled letter to Bristol Myers Squibb over misleading claims on cancer drug website for cancer drug Krazati. Read more here.


Source:Seeking Alpha
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
Aug 07, 2024 11:00am

Following regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful growth in demand Recent completion of Hemophilia A and gene editing technology sale to Novo Nordisk for up to $40 million reinforces exclusive focus on Abecma with streamlined cost structure Approximately $28 million (43%) quarter-on-quarter reduction in operating expenses due to completion of sale of R&D business to Regeneron on April 1, 2024 Ended quarter with approximately $202 million cash, cash equivalents, and marketable securities; cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ: TSVT ), today reported financial results and recent highlights for the second quarter ended June 30, 2024. "This year has been transformative for 2seventy, and we enter the second half in a strong financial and operational position, poised for commercial growth," said Chip Baird, CEO. "We dramatically reduced our cost structure and strengthened our balance sheet with the completion of the sale of our oncology R&D business to Regeneron and the sale of our Hemophilia A program and gene editing technology to Novo Nordisk.


Source:Benzinga
Bristol-Myers Squibb: Sell Now, Buy Later (Rating Downgrade)
Aug 07, 2024 00:20am

Bristol-Myers Squibb''s upgraded guidance is too small to improve prospects for H2 2024. Read more to see why I’m downgrading BMY stock to Sell.


Source:Seeking Alpha
Bristol-Myers Squibb: A Potential Comeback In Healthcare
Aug 06, 2024 18:32pm

No summary available.


Source:Seeking Alpha
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Aug 05, 2024 18:31pm

Agenus reports that Bristol Myers Squibb (NYSE: BMY) is … Full story available on Benzinga.com


Source:Benzinga
Bristol-Myers Squibb Company PFD CONV 2 goes ex dividend tomorrow
Aug 05, 2024 15:48pm

No summary available.


Source:Seeking Alpha